Treatment concept
The unique therapeutic approach proposed by CellProthera protected by various patents necessitate a simple blood sampling performed within 2 weeks following a severe AMI. The sampling will be preceded by a treatment period using GCSF over 6 days in order to mobilized the patient’s own stem cells into the blood stream. Within 12 hours the patient’s blood sample will be forwarded to the local certified Cell Therapy centre to be processed by a proprietary autaomated device for the preparation of the final graft product.
When injected into scar tissue within the heart wall, CD34+ cells have been shown experimentally in nude mice to be capable of engrafting in the damaged tissue and differentiating into mature myocardial and endothelial cells. These engrafted cells have been shown to express various proteins that are important components of contractile function.
By using ASC obtained from a patient’s own body, this therapeutic approach avoids all challenges currently faced by other types of cell-based clinical therapies including tissue rejection, immunosuppressive treatments and instances of the cells differentiating into cells other than cardiomyocytes and vessels at the contact of the myocardial ischemic zone.
The overall process of cardiac grafting become a simple treatment for interventional cardiologist as easy as placing a stent in coronary bed. This can be considered as a revolution for the management of patients suffering severe AMI compared to existing treatments.
- Ethical technical process (autologous adult stem cells)
- Specific benefits:
- Improvement of long term cardiac function reducing mortality associated with AMI and drastically increasing quality of life
- Impact on overall disease cost by reduction of hospital stay representing 85% of Congestive Heart Failure global cost)
- Reduction in the need for pharmacological treatments
- No need to renew the grafting even as a non traumatic approach similar to stenting technique
- Unique alternative to heart transplant
